DelveInsight’s, “Post-Traumatic Stress Disorder Pipeline Insight, 2023,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Post-Traumatic Stress Disorder pipeline landscape. It covers the pipeline drug profiles, including Post-Traumatic Stress Disorder clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Post-Traumatic Stress Disorder pipeline report, detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Post-traumatic stress disorders collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Post-Traumatic Stress Disorder Pipeline Report
To explore more information on the latest breakthroughs in the Post-Traumatic Stress Disorder pipeline treatment landscape of the report, click here @ Post-Traumatic Stress Disorder Pipeline Outlook
Post-Traumatic Stress Disorder Overview
Post-traumatic stress disorder (PTSD) is a psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, or rape or who have been threatened with death, sexual violence or serious injury Some experiences, like the sudden, unexpected death of a loved one, can cause PTSD. Symptoms usually begin early, within 3 months of the traumatic incident, but sometimes they begin years afterward. Symptoms must last more than a month and be severe enough to interfere with relationships or work to be considered PTSD. Treatment usually psychotherapy and counseling, medication, or a combination.
Recent Developments Activities in the Post-Traumatic Stress Disorder Treatment Landscape
Request a sample and discover the recent advances in Post-Traumatic Stress Disorder Ongoing Clinical Trial Analysis and Medications, click here @ Post-Traumatic Stress Disorder Treatment Landscape
Post-traumatic stress disorders Emerging Drugs Profile
Brexpiprazole: Otsuka Pharmaceutical Development & Commercialization
Brexpiprazole is a Dopamine D2 receptor partial agonists being developed by Otsuka Pharmaceutical Development and Commercialization in a Phase III clinical trial for Post-Traumatic stress disorder. Brexpiprazole as Combination Therapy with Sertraline is tested in the Adults with Post-traumatic Stress Disorder. This trail is expected to get completed in June 2022.
NBTX-001 Xenon Inhaler: Nobilis Therapeutics
NBTX-001 is a uniquely engineered drug-device combination specifically designed to provide a differentiated pharmaceutical therapy for the treatment of PTSD. Its proprietary portable inhalation device delivers a xenon gas mixture that has an exceptional safety profile proven by decades of clinical use in general anesthesia. Xenon is a competitive NMDA receptor antagonist devoid of dissociative and habit-forming properties. XBTX-001 is under phase II/III for PTSD.
BNC 210: Bionomics
BNC210 is Bionomics’ proprietary molecule in development for the treatment of Social Anxiety Disorder (SAD), Post-Traumatic Stress Disorder (PTSD) and anxiety disorders. Bionomics is conducting a phase II trial to assess the effects of BNC210 compared to placebo on PTSD symptom severity. BNC 210 blocks the alpha7 nicotinic acetylcholine receptor. BNC210 has also demonstrated a well-tolerated safety profile which indicates a potential advantage over currently available medications for the treatment of SAD, PTSD and anxiety disorders (e.g. antidepressants, benzodiazepines).
Lu AG06466: H. Lundbeck A/S
Lu AG06466 is a small molecule and a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). H.Lundbeck A/S is conducting Phase I trial for Lu AG06466 after multiple doses of 30 milligrams (mg) in participants with PTSD.
Post-traumatic Stress Disorder Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Post-traumatic stress disorders. The companies which have their Post-traumatic stress disorders drug candidates in the most advanced stage, i.e. phase III include, Otsuka Pharmaceutical Development & Commercialization.
For further information, refer to the detailed Post-traumatic Stress Disorder Unmet Needs, Post-traumatic Stress Disorder Market Drivers, and Market Barriers, click here for Post-traumatic Stress Disorder Ongoing Clinical Trial Analysis
Scope of the Post-traumatic Stress Disorder Pipeline Report
Dive deep into rich insights for drugs for Post-traumatic stress disorders Market Drivers and Post-traumatic stress disorders Market Barriers, click here @ Post-traumatic stress disorders Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Post-traumatic Stress Disorder Mergers and acquisitions, Post-traumatic Stress Disorder Licensing activities @ Post-traumatic Stress Disorder Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NV 89107Country: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services